AR035959A1 - Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion - Google Patents
Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccionInfo
- Publication number
- AR035959A1 AR035959A1 ARP020101441A ARP020101441A AR035959A1 AR 035959 A1 AR035959 A1 AR 035959A1 AR P020101441 A ARP020101441 A AR P020101441A AR P020101441 A ARP020101441 A AR P020101441A AR 035959 A1 AR035959 A1 AR 035959A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- heteroaryl
- alkenyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 16
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- -1 cyano, acetoxymethyl Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la cual: R1 es seleccionado entre el grupo que consiste en alquilo C1-8, alquenilo C2-8, R42N-alquilo C1-6, R42NC(=O)-alquilo C1-6, R4O-alquilo C1-6, R4OC(=O)-alquilo C1-6, R4C(=O)-alquilo C1-6, R4C(=O)NR4-alquilo C1-6, R42NSO2-alquilo C1-6, R4CSO2NR4-alquilo C1-6, R42NC(=O)NR4-alquilo C1-6, R42NSO2NR4-alquilo C1-6, aril-alquilo C1-6, aroil-alquilo C1-6, heteroaril-alquilo C1-6, heteroaroil-alquilo C1-6, heterocicloalquil C3-8- alquilo C1-6, heteroaril-alquilo C1-6 bicíclico y heteroaroil- alquilo C1-6 bicíclico; las porciones R1 comprenden alquenilo C2-8 no sustituido y alquilo C1-8 no sustituido o sustituido con una o más porciones seleccionadas independientemente del grupo que consiste en halógeno, ciano, acetoximetilo y nitro; Ar es una porción arilo optativamente sustituida; R2 es alquilo C1-6 no sustituido o sustituido en los carbonos 1-6 con uno o más sustituyentes flúor o cicloalquilo C3-6; R3 se selecciona del grupo que consiste en: fórmulas (2), (3), (4), (5), (6), (7), (8) y (9); R4 es una porción seleccionada independientemente del grupo que consiste en -H, -alquilo C1-6, -alquenilo C2-6 y -alquinilo C2-6; las porciones R5 se seleccionan independientemente del grupo que consiste en -H, -alquilo C1-6, -alquenilo C2-6 y heterociclilo; las porciones R6 se seleccionan independientemente del grupo que consiste en: -H, -alquilo C1-6, -alquenilo C2-6 y alcanoílo C1-6, heterociclilo, heterociclil-alquilo C1-3, arilo, aril-alquilo C1-3, heteroarilo, heteroaril-alquilo C1-3, heteroarilo bicíclico, y heteroaril-alquilo C1-3 bicíclico; R5 y R6 pueden combinarse para formar un heterociclo de 5-7 miembros; X se selecciona del grupo que consiste en -C(R5)2-, -NR5-, C(=O)-, -CH2-CH2-, -CH=CH-, -O-, -C(R)(R')-, y -S(O)n- (donde n = 0, 1 o 2), donde R y R' = alquilo C1-6, OR'', o H, y R'' = H o alquilo C1-6; e Y es carbono o nitrógeno, en donde si R1 representa R42N-alquilo C1-6, en donde ambas apariciones de R4 representan -alquilo C1-6 entonces R3 no es acetilo, -NH2 o acetamido. Uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composición farmacéutica, y método de reducción
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101387A SE0101387D0 (sv) | 2001-04-20 | 2001-04-20 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035959A1 true AR035959A1 (es) | 2004-07-28 |
Family
ID=20283822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101441A AR035959A1 (es) | 2001-04-20 | 2002-04-19 | Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7030139B2 (es) |
| EP (1) | EP1390350A1 (es) |
| JP (1) | JP2004528334A (es) |
| KR (1) | KR20040022421A (es) |
| CN (1) | CN1250531C (es) |
| AR (1) | AR035959A1 (es) |
| BG (1) | BG108271A (es) |
| BR (1) | BR0208907A (es) |
| CA (1) | CA2444381A1 (es) |
| CZ (1) | CZ20032833A3 (es) |
| EE (1) | EE200300524A (es) |
| HU (1) | HUP0303825A3 (es) |
| IL (1) | IL158142A0 (es) |
| IS (1) | IS6971A (es) |
| MX (1) | MXPA03009558A (es) |
| MY (1) | MY134568A (es) |
| NO (1) | NO20034665L (es) |
| NZ (1) | NZ528403A (es) |
| PL (1) | PL366517A1 (es) |
| RU (1) | RU2312864C2 (es) |
| SE (1) | SE0101387D0 (es) |
| SK (1) | SK13032003A3 (es) |
| UA (1) | UA76743C2 (es) |
| WO (1) | WO2002085866A1 (es) |
| ZA (1) | ZA200307752B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533748A (ja) | 2002-03-08 | 2005-11-10 | シグナル ファーマシューティカルズ，インコーポレイテッド | 増殖性障害および癌を治療、予防、または管理するための併用療法 |
| SE0203070D0 (en) * | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
| EP1608628A2 (en) * | 2003-03-17 | 2005-12-28 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| SE0300908D0 (sv) * | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| SE0301699D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0301698D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0301701D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| WO2005000829A1 (ja) * | 2003-06-26 | 2005-01-06 | Takeda Pharmaceutical Company Limited | カンナビノイド受容体調節剤 |
| US7157471B2 (en) * | 2003-08-25 | 2007-01-02 | Boehringer Ingelheim International Gmbh | Haloalkyl- and piperidine-substituted benzimidazole-derivatives |
| WO2005021547A2 (en) * | 2003-08-28 | 2005-03-10 | Pharmaxis Pty Ltd. | Heterocyclic cannabinoid cb2 receptor antagonists |
| SE0302570D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302573D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302572D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302571D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| CA2539632A1 (en) * | 2003-10-16 | 2005-04-28 | Cara Therapeutics, Inc. | Amide or thioamide derivatives and their use in the treatment of pain |
| WO2006033627A1 (en) * | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Compounds, compositions containing them, preparation thereof and uses thereof iiii |
| EP1797075A1 (en) * | 2004-09-24 | 2007-06-20 | AstraZeneca AB | Benzimidazole derivatives and their use as cannabinoid receptor ligands |
| EP1794150A1 (en) * | 2004-09-24 | 2007-06-13 | AstraZeneca AB | Benzimidazole derivatives and their use as cannabinoid receptor ligands I |
| JP2008514592A (ja) * | 2004-09-24 | 2008-05-08 | アストラゼネカ・アクチエボラーグ | ベンゾイミダゾール誘導体、それらを含有する組成物、それらの製造及びそれらの使用ｉｉｉ |
| CN101052639B (zh) * | 2004-09-24 | 2010-10-27 | 阿斯利康(瑞典)有限公司 | 苯并咪唑衍生物、含有它们的组合物、其制备方法和其用途 |
| CA2581232C (en) * | 2004-09-24 | 2015-04-07 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i |
| EP1797070A1 (en) * | 2004-09-24 | 2007-06-20 | AstraZeneca AB | Compounds, compositions containing them, preparations thereof and uses thereof ii |
| EP1797076A1 (en) * | 2004-09-24 | 2007-06-20 | AstraZeneca AB | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| BRPI0515897A (pt) | 2004-09-24 | 2008-08-12 | Astrazeneca Ab | composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto |
| JP2008517959A (ja) | 2004-10-27 | 2008-05-29 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なインドール又はベンゾイミダゾール誘導体 |
| ATE417830T1 (de) * | 2004-11-02 | 2009-01-15 | Pfizer | Sulfonylbenzimidazolderivate |
| SE0402763D0 (sv) * | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Nitro indazole derivatives |
| SE0402762D0 (sv) * | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
| WO2006097808A1 (en) * | 2005-03-15 | 2006-09-21 | Pfizer Japan Inc. | Benzimidazolone derivatives as cb2 receptor ligands |
| US20100261796A1 (en) | 2005-04-28 | 2010-10-14 | Ferring B.V. | Use of Novel Compounds for IBD Treatment |
| TW200736227A (en) | 2005-12-23 | 2007-10-01 | Astrazeneca Ab | New compounds III |
| WO2007091950A1 (en) * | 2006-02-07 | 2007-08-16 | Astrazeneca Ab | Benzimidazoles and imidazopyridines useful in the treatment of diseases or disorders associated with cannabinoid receptor 2 (cb2) such as pain |
| US7700618B2 (en) | 2006-03-06 | 2010-04-20 | Pfizer Inc | Sulfonyl benzimidazole derivatives |
| TW200745049A (en) | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
| TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
| TW200808772A (en) * | 2006-06-13 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
| AU2007271241A1 (en) * | 2006-07-04 | 2008-01-10 | Janssen Pharmaceutica Nv | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| FR2907784B1 (fr) * | 2006-10-27 | 2009-02-13 | Sod Conseils Rech Applic | Derives phenyliques et leur utilisation comme medicament |
| WO2009116074A2 (en) * | 2008-02-13 | 2009-09-24 | Cadila Healthcare Limited | Substituted benzimidazoles as cannabinoid modulator |
| US20120277296A1 (en) | 2009-07-23 | 2012-11-01 | Sophie Lotersztajn | Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease |
| US20110086853A1 (en) * | 2009-10-08 | 2011-04-14 | William Brown | Therapeutic Compounds |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| KR101837759B1 (ko) | 2010-02-18 | 2018-04-26 | 브이티브이 테라퓨틱스 엘엘씨 | 치환된 융합 이미다졸 유도체, 약학적 조성물, 및 그것의 사용 방법 |
| AU2012284184B2 (en) | 2011-07-18 | 2017-03-09 | Merck Patent Gmbh | Benzamides |
| CN102977056B (zh) * | 2012-11-28 | 2014-11-26 | 深圳万乐药业有限公司 | N-苄氧羰基-3-氟-4-吗啉基苯胺的合成方法 |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| WO2017157332A1 (zh) * | 2016-03-18 | 2017-09-21 | 江苏恒瑞医药股份有限公司 | 芳香酰胺类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2945044A (en) * | 1957-07-12 | 1960-07-12 | Ciba Pharm Prod Inc | Certain 1-(diethyl-aminoethyl), 5-amino, 2-benzyl or substituted benzyl, benzimidazoles |
| FR1481049A (fr) | 1965-11-25 | 1967-05-19 | France Ministre Des Armees | Nouveaux dialkylaminoalkyl-1 p-alkoxyphényl alkyl-2 benzimidazoles 5-substitués |
| IL112235A (en) * | 1994-01-03 | 2000-06-29 | Acea Pharm Inc | 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them |
| CA2192206A1 (en) * | 1994-06-10 | 1995-12-21 | Bernhard Kohl | Thiopyridines for use in the control of helicobacter bacteria |
| SE0203070D0 (en) * | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
-
2001
- 2001-04-20 SE SE0101387A patent/SE0101387D0/xx unknown
-
2002
- 2002-04-18 CN CNB028085779A patent/CN1250531C/zh not_active Expired - Fee Related
- 2002-04-18 NZ NZ528403A patent/NZ528403A/en unknown
- 2002-04-18 SK SK1303-2003A patent/SK13032003A3/sk not_active Application Discontinuation
- 2002-04-18 BR BR0208907-6A patent/BR0208907A/pt not_active IP Right Cessation
- 2002-04-18 CA CA002444381A patent/CA2444381A1/en not_active Abandoned
- 2002-04-18 WO PCT/SE2002/000769 patent/WO2002085866A1/en not_active Ceased
- 2002-04-18 MY MYPI20021423A patent/MY134568A/en unknown
- 2002-04-18 HU HU0303825A patent/HUP0303825A3/hu unknown
- 2002-04-18 RU RU2003129638/04A patent/RU2312864C2/ru not_active IP Right Cessation
- 2002-04-18 US US10/474,549 patent/US7030139B2/en not_active Expired - Fee Related
- 2002-04-18 UA UA2003108942A patent/UA76743C2/uk unknown
- 2002-04-18 KR KR10-2003-7013622A patent/KR20040022421A/ko not_active Ceased
- 2002-04-18 EP EP02764120A patent/EP1390350A1/en not_active Withdrawn
- 2002-04-18 JP JP2002583393A patent/JP2004528334A/ja active Pending
- 2002-04-18 EE EEP200300524A patent/EE200300524A/xx unknown
- 2002-04-18 IL IL15814202A patent/IL158142A0/xx unknown
- 2002-04-18 PL PL02366517A patent/PL366517A1/xx not_active Application Discontinuation
- 2002-04-18 MX MXPA03009558A patent/MXPA03009558A/es active IP Right Grant
- 2002-04-18 CZ CZ20032833A patent/CZ20032833A3/cs unknown
- 2002-04-19 AR ARP020101441A patent/AR035959A1/es not_active Application Discontinuation
-
2003
- 2003-09-29 IS IS6971A patent/IS6971A/is unknown
- 2003-10-03 ZA ZA200307752A patent/ZA200307752B/en unknown
- 2003-10-14 BG BG108271A patent/BG108271A/bg unknown
- 2003-10-17 NO NO20034665A patent/NO20034665L/no not_active Application Discontinuation
-
2006
- 2006-01-04 US US11/325,124 patent/US20060135554A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EE200300524A (et) | 2004-02-16 |
| NZ528403A (en) | 2005-05-27 |
| ZA200307752B (en) | 2005-01-03 |
| JP2004528334A (ja) | 2004-09-16 |
| MY134568A (en) | 2007-12-31 |
| NO20034665L (no) | 2003-12-10 |
| SK13032003A3 (sk) | 2005-01-03 |
| US20060135554A1 (en) | 2006-06-22 |
| SE0101387D0 (sv) | 2001-04-20 |
| CZ20032833A3 (en) | 2004-05-12 |
| BG108271A (bg) | 2004-12-30 |
| CA2444381A1 (en) | 2002-10-31 |
| HUP0303825A2 (hu) | 2004-03-01 |
| US20040116465A1 (en) | 2004-06-17 |
| PL366517A1 (en) | 2005-02-07 |
| IS6971A (is) | 2003-09-29 |
| BR0208907A (pt) | 2004-04-20 |
| HUP0303825A3 (en) | 2005-06-28 |
| MXPA03009558A (es) | 2004-02-12 |
| UA76743C2 (uk) | 2006-09-15 |
| RU2312864C2 (ru) | 2007-12-20 |
| EP1390350A1 (en) | 2004-02-25 |
| IL158142A0 (en) | 2004-03-28 |
| CN1503787A (zh) | 2004-06-09 |
| KR20040022421A (ko) | 2004-03-12 |
| NO20034665D0 (no) | 2003-10-17 |
| WO2002085866A1 (en) | 2002-10-31 |
| CN1250531C (zh) | 2006-04-12 |
| US7030139B2 (en) | 2006-04-18 |
| RU2003129638A (ru) | 2005-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035959A1 (es) | Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion | |
| RU93058253A (ru) | Соединения-антибиотики, способы их получения, промежуточные соединения, фармкомпозиция, способ лечения | |
| IS4206A (is) | Hliðstæðar aðferðir til framleiðslu á andróstenónafleiðu og milliefni notuð í aðferðunum | |
| PT74563B (en) | Process for preparing benzamide derivatives and pharmaceutical compositions containing the same | |
| AR045822A1 (es) | Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos | |
| KR920018030A (ko) | 치환된 이미다졸-2-온의 유도체 및 이의 제조방법 | |
| ES465225A1 (es) | Procedimiento para la preparacion de n-cicloalcohilmetil-2- fenilamino-imidazolinas-(2). | |
| ATE444965T1 (de) | Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
| SE7605819L (sv) | Nya propargyl-2-fenylaminoimidazolin-(2), dess syraadditionssalter, lekemedel innehallande dessa och forfarande for framstellning derav | |
| ATE204278T1 (de) | Serotoninergische ergolin derivate | |
| AR045820A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos | |
| KR920016456A (ko) | 5-(치환 아미노) -1,2,4-트리아졸로 [1,5-a]피리미딘 유도체 | |
| AR033429A1 (es) | Derivados del acido alcoxicarbonilamino-heteroarilcarboxilico, su uso, un procedimiento para prepararlos y composiciones farmaceuticas que los comprenden | |
| AR035698A1 (es) | Derivados de guanidina biciclicos, procedimiento para preparar estos compuestos y composicion farmaceutica | |
| DE3878967D1 (de) | 17-aza-20,21-dinoreburnameninderivate, verfahren und zwischenprodukte zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen. | |
| DE69320896D1 (de) | Antibiotische Carbapenemverbindungen | |
| ATE22081T1 (de) | Substituierte thienobenzodiazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
| DE3361437D1 (en) | 4-hydroxy-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxides, process for their preparation, their use and therapeutic agents containing them | |
| DE3481059D1 (de) | Neue 11-piperazinyl-5h-imidazo(2,1-c)(1,4)benzodiazepine, verfahren zu ihrer herstellung und zwischenprodukte und erstere enthaltende arzneimittel. | |
| ATE7913T1 (de) | Substituierte 2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben. | |
| ES534033A0 (es) | Procedimiento para la preparacion de derivados de acridanona. | |
| AR015235A1 (es) | Compuestos derivados de pirazol [1,5-b]piridazina, proceso para su preparacion, composiciones y su uso para la fabricacion de un agente terapeutico. | |
| TH10903B (th) | [(เบนโซไดออกซาน, เบนโซฟิวราน หรือเบนโซพิราน)แอลคิลอะมิโน] แอลคิล ซับสทิทิวเทด กัวนิดีน ในฐานะเป็นสารที่เลือกเฉพาะทำการให้หลอดโลหิตตีบตัว |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |